CA2101417A1 - Prophylaxie et traitement de la maladie d'alzheimer - Google Patents

Prophylaxie et traitement de la maladie d'alzheimer

Info

Publication number
CA2101417A1
CA2101417A1 CA002101417A CA2101417A CA2101417A1 CA 2101417 A1 CA2101417 A1 CA 2101417A1 CA 002101417 A CA002101417 A CA 002101417A CA 2101417 A CA2101417 A CA 2101417A CA 2101417 A1 CA2101417 A1 CA 2101417A1
Authority
CA
Canada
Prior art keywords
calpain
alzheimer
disease
journal
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002101417A
Other languages
English (en)
Inventor
Ken-Ichi Saito
Ralph A. Nixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mclean Hospital Corp
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of CA2101417A1 publication Critical patent/CA2101417A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002101417A 1992-08-14 1993-07-27 Prophylaxie et traitement de la maladie d'alzheimer Abandoned CA2101417A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93064792A 1992-08-14 1992-08-14
US930,647 1992-08-14

Publications (1)

Publication Number Publication Date
CA2101417A1 true CA2101417A1 (fr) 1994-02-15

Family

ID=25459574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002101417A Abandoned CA2101417A1 (fr) 1992-08-14 1993-07-27 Prophylaxie et traitement de la maladie d'alzheimer

Country Status (4)

Country Link
JP (1) JPH06172211A (fr)
KR (1) KR940003550A (fr)
CA (1) CA2101417A1 (fr)
TW (1) TW268896B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201524T3 (es) * 1997-09-04 2004-03-16 Nippon Chemiphar Co., Ltd. Derivados de epoxisuccinamida.

Also Published As

Publication number Publication date
KR940003550A (ko) 1994-03-12
JPH06172211A (ja) 1994-06-21
TW268896B (fr) 1996-01-21

Similar Documents

Publication Publication Date Title
EP0580161A1 (fr) Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
Pelletier et al. Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level
Pelletier et al. Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase
JP2010031059A (ja) 筋萎縮性側索硬化症を処置するためのプラミペキソールの使用
JP4316672B2 (ja) ラムノリピド類の免疫活性
EP1033910A1 (fr) Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers
JP3010210B1 (ja) マトリックスメタロプロテアーゼ産生阻害剤
JPH06122663A (ja) 過度のコラーゲン破壊を防止する薬剤
US20070265208A1 (en) Association of calpain inhibitors and reactive oxygen species trapping agents
JP2005516911A6 (ja) 筋萎縮性側索硬化症を処置するためのプラミペキソールの使用
US6593362B2 (en) Non-peptidic cyclophilin binding compounds and their use
DE69814072T2 (de) Caspases und apoptosis
US20040014678A1 (en) Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytoc pathway
JPH03130222A (ja) 新規な治療用組成物
CA2101417A1 (fr) Prophylaxie et traitement de la maladie d'alzheimer
JP2013531032A (ja) マクロラクチンａ及びその誘導体を有効成分として含有する抗血管新生組成物
Yuen et al. Section Review: Central & Peripheral Nervous Systems: Therapeutic potential of calpain inhibitors in neurodegenerative disorders
EP0664127B1 (fr) Composition pharmaceutiques contenant des dérivés de l'isoquinoline
KR101270123B1 (ko) 항산화용 조성물
Olds et al. Differential immunoregulation of granulomatous inflammation, portal hypertension, and hepatic fibrosis in murine schistosomiasis mansoni.
CN111867580B (zh) 用于预防或改善脱发的包含有效成分董尼酮的组合物
JPH10139665A (ja) トログリタゾンを含有するグルタチオン還元酵素活性増強剤
CA2207943A1 (fr) Agent therapeutique pour les maladies articulaires
EP0149847A2 (fr) Agent thérapeutique et préventif contenant le dolichol
KR100751051B1 (ko) 관절염 치료용 약제학적 조성물

Legal Events

Date Code Title Description
FZDE Dead